{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:36:12Z","timestamp":1789900572250,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd009841","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T00:00:00Z","timestamp":1427328000000}}],"reference-count":123,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009841.pub2","type":"journal-article","created":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T16:36:55Z","timestamp":1427474215000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis"],"prefix":"10.1002","author":[{"given":"Sanjay","family":"Patel","sequence":"first","affiliation":[{"name":"University of Liverpool; Department of Women's and Children's Health; Alder Hey Children's NHS Foundation Trust Eaton Road Liverpool Merseyside UK L12 2AP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian P","family":"Sinha","sequence":"additional","affiliation":[{"name":"University of Liverpool; Department of Women's and Children's Health; Alder Hey Children's NHS Foundation Trust Eaton Road Liverpool Merseyside UK L12 2AP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Dwan","sequence":"additional","affiliation":[{"name":"University of Liverpool; Department of Biostatistics; Alder Hey Children's NHS Foundation Trust Eaton Road Liverpool England UK L12 2AP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Echevarria","sequence":"additional","affiliation":[{"name":"Institute of Cellular Medicine, Newcastle University; 4th Floor, William Leech Building Framlington Place Newcastle UK NE2 4HH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schechter","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University; Division of Pulmonary Medicine; Richmond Virginia USA 23298-0315"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W","family":"Southern","sequence":"additional","affiliation":[{"name":"University of Liverpool; Department of Women's and Children's Health; Alder Hey Children's NHS Foundation Trust Eaton Road Liverpool Merseyside UK L12 2AP"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,3,26]]},"reference":[{"issue":"S32","key":"10.1002\/14651858.CD009841.pub2-BIB0001|cit1","first-page":"296, Abstract n","article-title":"Improvement in sweat chloride concentration by the CFTR potentiator VX-770 in subjects with cystic fibrosis and the G551D-CFTR mutation [abstract","volume":"44","author":"Accurso","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"21","key":"10.1002\/14651858.CD009841.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD009841.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1-33 online","DOI":"10.1056\/NEJMoa0909825","article-title":"Online supplementary appendix to \"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation\" [online]","volume":"363","author":"Accurso","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD009841.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1991-2003 onlin","DOI":"10.1056\/NEJMoa0909825","article-title":"Online supplementary material (disclosure forms) to \"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation\" [online]","volume":"363","author":"Accurso","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD009841.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1-121 online","DOI":"10.1056\/NEJMoa0909825","article-title":"Online supplementary material (protocol) to \"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation\" [online]","volume":"363","author":"Accurso","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"S25, Abstract n","DOI":"10.1016\/S1569-1993(09)60101-6","article-title":"Final results of a 14-and 28-day study of VX-770 in subjects with CF [abstract]","volume":"8 Suppl 2","author":"Accurso","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S1","key":"10.1002\/14651858.CD009841.pub2-BIB0007|cit7","first-page":"295, Abstract n","article-title":"Interim results of phase 2a study of VX-770 to evaluate safety, pharmacokinetics, and biomarkers of CFTR activity in cystic fibrosis subjects with G551D [abstract]","volume":"43","author":"Accurso","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD009841.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"139-147 online","DOI":"10.1016\/j.jcf.2013.09.007","article-title":"Online Data Supplement to \"Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data\"","volume":"13","author":"Accurso","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD009841.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2013.09.007","article-title":"Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data","volume":"13","author":"Accurso","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD009841.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1517\/13543784.2011.554823","article-title":"Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Evaluation of: Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. New England Journal of Medicine 2010;363(21):1991-2003","volume":"20","author":"Antoniu","year":"2011","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"S32","key":"10.1002\/14651858.CD009841.pub2-BIB0011|cit11","first-page":"287, Abstract n","article-title":"Effect of VX-770, a CFTR potentiator, on spirometry and QOL assessment in subjects with CF and the G551D-CFTR mutation [abstract]","volume":"44","author":"Boyle","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"S32","key":"10.1002\/14651858.CD009841.pub2-BIB0012|cit12","first-page":"288, Abstract n","article-title":"NPD evaluation of ion transport in G551D CF patients treated with a CFTR potentiator [abstract]","volume":"44","author":"Clancy","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"S20, Abstract n","DOI":"10.1016\/S1569-1993(10)60075-6","article-title":"Parallel effects of VX-770 on transepithelial potential difference in vitro and in vivo [abstract]","volume":"9 Suppl 1","author":"Rowe","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"7","key":"10.1002\/14651858.CD009841.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"e66955","DOI":"10.1371\/journal.pone.0066955","article-title":"Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation","volume":"8","author":"Rowe","year":"2013","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0015|cit15","first-page":"319, Abstract n","article-title":"Corresponding effects of VW-770 on NPD in vivo & human bronchial epithelial (HBE) cells in vitro","volume":"45 Suppl 33","author":"Rowe","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"S31","key":"10.1002\/14651858.CD009841.pub2-BIB0016|cit16","first-page":"314, Abstract n","article-title":"Relationship of VX-770 activity on CFTR function in a cell culture system to the activity observed in a clinical study of VX-770 [abstract]","volume":"43","author":"Goor","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"S34","key":"10.1002\/14651858.CD009841.pub2-BIB0017|cit17","first-page":"283, Abstract n","article-title":"VX-770 in subjects 6 to 11 years with cystic fibrosis and the G551D-CFTR mutation [abstract]","volume":"46","author":"Aherns","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"S13, Abstract n","DOI":"10.1016\/S1569-1993(12)60041-1","article-title":"Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation [abstract]","volume":"11 Suppl 1","author":"Borowitz","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S35","key":"10.1002\/14651858.CD009841.pub2-BIB0019|cit19","first-page":"298, Abstract n","article-title":"Nutritional status measures among persons with CF carrying the G551D-CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials [abstract]","volume":"47","author":"Borowitz","year":"2012","journal-title":"Pediatric Pulmonology"},{"issue":"11","key":"10.1002\/14651858.CD009841.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation","volume":"187","author":"Davies","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"11","key":"10.1002\/14651858.CD009841.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1219-1225 onlin","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Online Supplement to \"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation\" [online]","volume":"187","author":"Davies","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S13, Abstract n","DOI":"10.1016\/S1569-1993(12)60043-5","article-title":"Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D-CFTR mutation [abstract]","volume":"11 Suppl 1","author":"Davies","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0023|cit23","first-page":"298, Abstract n","article-title":"Effect of ivacaftor in patients with cystic fibrosis and the G551D-CFTR mutation who have baseline FEV >90% of predicted [abstract]","volume":"48 Suppl 36","author":"Elborn","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S63, Abstract n","DOI":"10.1016\/S1569-1993(13)60200-3","article-title":"Pulmonary exacerbations in CF patients with the G551D-CFTR mutation treated with ivacaftor [abstract]","volume":"12 Suppl 1","author":"Flume","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S2213-2600(14)70218-8","article-title":"Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)","volume":"2","author":"McKone","year":"2014","journal-title":"The Lancet. Respiratory Medicine"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"S62, Abstract n","DOI":"10.1016\/S1569-1993(13)60195-2","article-title":"Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis [abstract]","volume":"12 Suppl 1","author":"Plant","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0027|cit27","first-page":"297, Abstract n","article-title":"Patient-reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation [abstract]","volume":"47 Suppl 35","author":"Quittner","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"S67, Abstract n","DOI":"10.1016\/S1569-1993(12)60212-4","article-title":"Patient-reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation [abstract]","volume":"11 Suppl 1","author":"Quittner","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0029|cit29","first-page":"284, Abstract n","article-title":"VX-770 in subjects with CF and homozygous for the F508del-CFTR mutation [abstract]","volume":"46 Suppl 34","author":"Flume","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S16, Abstract n","DOI":"10.1016\/S1569-1993(11)60080-5","article-title":"VX-770 in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation [abstract]","volume":"10 Suppl 1","author":"Flume","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD009841.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1378\/chest.11-2672","article-title":"Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation","volume":"142","author":"Flume","year":"2012","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD009841.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"718-724 online","DOI":"10.1378\/chest.11-2672","article-title":"Online Supplement to \"Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation\" [online]","volume":"142","author":"Flume","year":"2012","journal-title":"Chest"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"S13, Abstract n","DOI":"10.1016\/S1569-1993(12)60041-1","article-title":"Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation [abstract]","volume":"11 Suppl 1","author":"Borowitz","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0034|cit34","first-page":"298, Abstract n","article-title":"Nutritional status measures among persons with CF carrying the G551D-CFTR mutation who received ivacaftor or placebo in phase 3 clinical trials [abstract]","volume":"47 Suppl 35","author":"Borowitz","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0035|cit35","first-page":"298, Abstract n","article-title":"Effect of ivacaftor in patients with cystic fibrosis and the G551D-CFTR mutation who have baseline FEV >90% of predicted [abstract]","volume":"48 Suppl 36","author":"Elborn","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S63, Abstract n","DOI":"10.1016\/S1569-1993(13)60200-3","article-title":"Pulmonary exacerbations in CF patients with the G551D-CFTR mutation treated with ivacaftor [abstract]","volume":"12 Suppl 1","author":"Flume","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"S67, Abstract n","DOI":"10.1016\/S1569-1993(12)60213-6","article-title":"Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation [abstract]","volume":"11 Suppl 1","author":"Griese","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"S13, Abstract n","DOI":"10.1016\/S1569-1993(12)60042-3","article-title":"Long-term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation [abstract]","volume":"11 Suppl 1","author":"McKone","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S2213-2600(14)70218-8","article-title":"Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)","volume":"2","author":"McKone","year":"2014","journal-title":"The Lancet. Respiratory Medicine"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"S62, Abstract n","DOI":"10.1016\/S1569-1993(13)60195-2","article-title":"Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis [abstract]","volume":"12 Suppl 1","author":"Plant","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0041|cit41","first-page":"297, Abstract n","article-title":"Patient-reported outcomes in phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation [abstract]","volume":"47 Suppl 35","author":"Quittner","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"S67, Abstract n","DOI":"10.1016\/S1569-1993(12)60212-4","article-title":"Patient-reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation [abstract]","volume":"11 Suppl 1","author":"Quittner","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S34","key":"10.1002\/14651858.CD009841.pub2-BIB0043|cit43","first-page":"286, Abstract n","article-title":"Efficacy and safety of VX-770 in subjects with cystic fibrosis and the G551D-CFTR mutation [abstract]","volume":"46","author":"Ramsey","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"18","key":"10.1002\/14651858.CD009841.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.1002\/14651858.CD009841.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1663-1672 onlin","DOI":"10.1056\/NEJMoa1105185","article-title":"Online Supplementary Appendix to \"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation\" [online]","volume":"365","author":"Ramsey","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0046|cit46","first-page":"298, Abstract n","article-title":"Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D-CFTR mutation [abstract]","volume":"48 Suppl 36","author":"Seliger","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"S62, Abstract n","DOI":"10.1016\/S1569-1993(13)60198-8","article-title":"Effect of withdrawal of ivacaftor therapy on CFTR channel activity and lung function in patients with cystic fibrosis [abstract]","volume":"12 Suppl 1","author":"Accurso","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"S6, Abstract no","DOI":"10.1016\/S1569-1993(14)60020-5","article-title":"The effect of ivacaftor treatment on lung ventilation defects, as measured by hyperpolarized helium-3 MRI, on patients with cystic fibrosis and a G551D-CFTR mutation [abstract]","volume":"13 Suppl 2","author":"Altes","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"S67, Abstract n","DOI":"10.1016\/S1569-1993(12)60215-X","article-title":"Hyperpolarized Gas MRI of ivacaftor therapy in subjects with cystic fibrosis who have the G551D-CFTR mutation [abstract]","volume":"11 Suppl 1","author":"Altes","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0050|cit50","first-page":"291, Abstract n","article-title":"Hyperpolarized gas MRI of ivacaftor therapy in persons with cystic fibrosis and the G551D-CFTR mutation [abstract]","volume":"47 Suppl 35","author":"Altes","year":"2012","journal-title":"Pediatric Pulmonology"},{"issue":"S34","key":"10.1002\/14651858.CD009841.pub2-BIB0051|cit51","first-page":"284, Abstract n","article-title":"Hyperpolarized helium-3 magnetic resonance imaging of CFTR potentiator therapy in subjects with cystic fibrosis and the G551D mutation [abstract]","volume":"46","author":"Altes","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"S14, Abstract n","DOI":"10.1016\/S1569-1993(13)60043-0","article-title":"Lumacaftor, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in CF patients with the F508del-CFTR mutation: phase 2 interim analysis [abstract]","volume":"12 Suppl 1","author":"Boyle","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0053|cit53","first-page":"315, Abstract n","article-title":"The investigational CFTR corrector, VX-809 (lumacaftor) co-administered with the oral potentiator ivacaftor improved CFTR and lung function in F509-8DEL homozygous patients: phase II study results [abstract]","volume":"47 Suppl 35","author":"Boyle","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0054|cit54","first-page":"287, Abstract n","article-title":"VX-809, an investigational CFTR corrector , in combination with VX-770, an investigational CFTR potentiator, in subjects with CF and homozygous for the F508DEL-CFTR Mutation [abstract]","volume":"46 Suppl 34","author":"Boyle","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"7","key":"10.1002\/14651858.CD009841.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"The Lancet. Respiratory Medicine"},{"issue":"7","key":"10.1002\/14651858.CD009841.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"527-38 online","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"Supplementary Appendix to \"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial.\" [online]","volume":"2","author":"Boyle","year":"2014","journal-title":"The Lancet. Respiratory Medicine"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0057|cit57","first-page":"278","article-title":"Nasal application of glycerol in DF508 cystic fibrosis patients [abstract]","volume":"26 Suppl 17","author":"Chadwick","year":"1998","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD009841.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/thoraxjnl-2011-200393","article-title":"Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation","volume":"67","author":"Clancy","year":"2012","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0059|cit59","first-page":"298, Abstract n","article-title":"A phase II, randomized, placebo-controlled, clinical trial of four doses of VX-809 in CF patients homozygous for the F508del CFTR mutation [abstract]","volume":"45 Suppl 33","author":"Clancy","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0060|cit60","first-page":"283, Abstract n","article-title":"Variability of nasal potential difference measurements in clinical testing of CFTR modulators [abstract]","volume":"46 Suppl 34","author":"Clancy","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"S20, Abstract n","DOI":"10.1016\/S1569-1993(10)60074-4","article-title":"Clinical evaluation of VX-809, a novel investigational oral F508del-CFTR corrector, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation [abstract]","volume":"9 Suppl 1","author":"Clancy","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"S62, Abstract n","DOI":"10.1016\/S1569-1993(13)60198-8","article-title":"Effect of withdrawal of ivacaftor therapy on CFTR channel activity and lung function in patients with cystic fibrosis [abstract]","volume":"12 Suppl 1","author":"Accurso","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0063|cit63","first-page":"311, Abstract n","article-title":"Lung clearance index to evaluate the effect of ivacaftor on lung function in subjects with CF who have the G551D-CFTR mutation and mild lung disease [abstract]","volume":"47 Suppl 35","author":"Davies","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"S15, Abstract n","DOI":"10.1016\/S1569-1993(12)60049-6","article-title":"Effect of ivacaftor on lung function in subjects with CF who have the G551D-CFTR mutation and mild lung disease: a comparison of lung clearance index (LCI) vs. spirometry [abstract]","volume":"11 Suppl 1","author":"Davies","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0065|cit65","first-page":"298, Abstract n","article-title":"Effect of ivacaftor in patients with cystic fibrosis and the G551D-CFTR mutation who have baseline FEV >90% of predicted [abstract]","volume":"48 Suppl 36","author":"Elborn","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0066|cit66","first-page":"282, Abstract n","article-title":"Lung clearance index as an outcome measure in cystic fibrosis clinical trials [abstract]","volume":"46 Suppl 34","author":"Ratjen","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"S14, Abstract n","DOI":"10.1016\/S1569-1993(13)60042-9","article-title":"VX-661, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation: interim analysis [abstract]","volume":"12 Suppl 1","author":"Donaldson","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0068|cit68","first-page":"157","article-title":"Phase 2 studies reveal additive effects of VX-661, an investigational CFTR corrector, and ivacaftor, a CFTR potentiator, in patients with CF who carry the F508Del-CFTR mutation","volume":"49 Suppl 38","author":"Pilewski","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"S64, Abstract n","DOI":"10.1016\/S1569-1993(13)60205-2","article-title":"The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease [abstract]","volume":"12 Suppl 1","author":"Ajayi","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"7","key":"10.1002\/14651858.CD009841.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S2213-2600(14)70100-6","article-title":"Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"2","author":"Kerem","year":"2014","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0071|cit71","first-page":"312, Abstract n","article-title":"Natural history of cystic fibrosis in patients with nonsense-mutation-mediated disease [abstract]","volume":"47 Suppl 35","author":"Kerem","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"S17, Abstract n","DOI":"10.1016\/S1569-1993(11)60084-2","article-title":"Phase 3 study of ataluren (PTC124\u00ae) in nonsense mutation cystic fibrosis (nmCF): baseline data [abstract]","volume":"10 Suppl 1","author":"Kerem","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0073|cit73","first-page":"314, Abstract n","article-title":"Phase 3 study of Ataluren (PTC124\u00ae) in nonsense mutation cystic fibrosis (NMCF): demographic & other baseline data [abstract]","volume":"45 Suppl 33","author":"Kerem","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"S70, Abstract n","DOI":"10.1016\/S1569-1993(14)60230-7","article-title":"The effect of Pseusdomonas aeruginosa infection on pulmonary function outcome in a cohort of patients with nonsense mutation cystic fibrosis [abstract]","volume":"13 Suppl 2","author":"Kerem","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"S15, Abstract n","DOI":"10.1016\/S1569-1993(13)60044-2","article-title":"Interim results of the phase 3 open- label study of ataluren in nonsense mutation cystic fibrosis (nmCF) [abstract]","volume":"12 Suppl 1","author":"Kerem","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0076|cit76","first-page":"295, Abstract n","article-title":"Pretreatment data from phase 3 study of Ataluren document significant disease burden in a subpopulation of patients with nonsense mutation cystic fibrosis [abstract]","volume":"46 Suppl 34","author":"Konstan","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0077|cit77","first-page":"298, Abstract n","article-title":"Use of different pulmonary exacerbation definitions in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis [abstract]","volume":"48 Suppl 36","author":"Konstan","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0078|cit78","first-page":"290, Abstract n","article-title":"Results of the Phase 3 study of ataluren in nonsense mutation in cystic fibrosis (NMCF) [abstract]","volume":"47 Suppl 35","author":"Rowe","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0079|cit79","first-page":"279, Abstract n","article-title":"The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense-mutation cystic fibrosis [abstract]","volume":"48 Suppl 36","author":"Rowe","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD009841.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ppul.10043","article-title":"Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis","volume":"33","author":"Ahrens","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"S17","key":"10.1002\/14651858.CD009841.pub2-BIB0081|cit81","first-page":"276","article-title":"Safety of a phase I double-blind placebo-controlled dose escalation trial of oral CPX in adult CF patients [abstract]","volume":"26","author":"Aitken","year":"1998","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD009841.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ppul.10041","article-title":"A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis","volume":"33","author":"McCarty","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0083|cit83","first-page":"276","article-title":"Multicenter phase I trial of CPX in adults patients with mild CF: results of nasal potential difference measurements [abstract]","volume":"Suppl 17","author":"McCarty","year":"1998","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0084|cit84","first-page":"263","article-title":"Effects of gentamicin on ion transport, MRNA and protein CFTR expression in patients with R1162X: A double blind placebo controlled study [abstract]","volume":"34 Suppl 24","author":"Pradal","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0085|cit85","unstructured":"Romano L Casciaro R Vanini P Zegarra-Moran O Negro I Minuto N Reduction of sweat ion concentrations following topical application of gentamicin in CF patients carrying nonsense mutations [abstract] Proceedings of 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria 2001 P11"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0086|cit86","first-page":"250","article-title":"Effects of topical applications of gentamicin on sweat test in CF patients carrying nonsense-mutations [abstract]","volume":"30 Suppl 20","author":"Romano","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD009841.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1164\/ajrccm.157.2.9706088","article-title":"A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function","volume":"157","author":"Rubenstein","year":"1998","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0088|cit88","first-page":"272","article-title":"A randomized, double blind, placebo-controlled trial of sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: Partial restoration of nasal epithelial CFTR function [abstract]","volume":"24 Suppl 14","author":"Rubenstein","year":"1997","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0089|cit89","first-page":"294","article-title":"A pilot trial of the combination of phenylbutyrate and genistein [abstract]","volume":"41 Suppl 29","author":"Rubenstein","year":"2006","journal-title":"Pediatric Pulmonology"},{"issue":"10","key":"10.1002\/14651858.CD009841.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1164\/rccm.201001-0137OC","article-title":"Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis","volume":"182","author":"Sermet-Gaudelus","year":"2010","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0091|cit91","first-page":"244","article-title":"Gentamicin causes functional expression of CFTR in CF patients carrying stop mutations: a double-blind placebo controlled trial [abstract]","volume":"30 Suppl 20","author":"Wilschanski","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD009841.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"A582","DOI":"10.1016\/S0016-5085(03)82949-9","article-title":"Restoration of CFTR function by gentamicin in cystic fibrosis patients carrying stop mutations: a double blind placebo controlled trial [abstract]","volume":"124","author":"Wilschanski","year":"2003","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1002\/14651858.CD009841.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","article-title":"Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations","volume":"349","author":"Wilschanski","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0094|cit94","first-page":"294","article-title":"PTC124 induces time-dependent improvements in chloride conductance and clinical parameters in patients with nonsense-mutation-mediated cystic fibrosis [abstract]","volume":"43 Suppl 31","author":"Kerem","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0095|cit95","first-page":"313","article-title":"Children with nonsense-mutation-mediated cystic fibrosis respond to investigational treatment with PTC124 [abstract]","volume":"43 Suppl 31","author":"Sermet-Gaudelus","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(08)60084-3","article-title":"PTC124 induces CFTR full-length production and activity in children with nonsense-mutation-mediated CF [abstract]","volume":"7 Suppl 2","author":"Sermet-Gaudelus","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(08)60085-5","article-title":"PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense -mutation-mediated CF [abstract]","volume":"7 Suppl 2","author":"Wilschanski","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD009841.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/mthe.2002.0639","article-title":"Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate","volume":"6","author":"Zeitlin","year":"2002","journal-title":"Molecular Therapy"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"S1, Abstract no","DOI":"10.1016\/S1569-1993(14)60004-7","article-title":"The effect of ivacaftor, a CFTR potentiator, in patients with cystic fibrosis and a non-G551D-CFTR gating mutation, the KONNECTION study [abstract]","volume":"13 Suppl 2","author":"Boeck","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0100|cit100","first-page":"292, Abstract n","article-title":"Ivacaftor, a CFTR potentiator, in cystic fibrosis patients who have a non-G551D-CFTR gating mutation: phase 3, part 1 results [abstract]","volume":"48 Suppl 36","author":"Boeck","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0102|cit101","doi-asserted-by":"crossref","unstructured":"Moss R Study of ivacaftor in subjects with cystic fibrosis who have the R117H-CFTR mutation (KONDUCT) Www.clinicaltrials.gov (www.clinicaltrials.gov) (accessed 22 Oct 2014) 2014","DOI":"10.1016\/S1569-1993(14)60137-5"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0101|cit102","first-page":"221, Abstract n","article-title":"Effects of ivacaftor in CF patients with R117H-CFTR [abstract]","volume":"49 Suppl 38","author":"Moss","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"S44, Abstract n","DOI":"10.1016\/S1569-1993(14)60137-5","article-title":"Ivacaftor treatment in patients with cystic fibrosis who have an R117H-CFTR mutation, the KONDUCT study [abstract]","volume":"13 Suppl 2","author":"Moss","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0104|cit104","unstructured":"Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function. Ongoing study September 2012."},{"key":"10.1002\/14651858.CD009841.pub2-BIB0105|cit105","unstructured":"Short-Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients. Ongoing study October 2013."},{"issue":"7","key":"10.1002\/14651858.CD009841.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.tips.2007.05.004","article-title":"Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis","volume":"28","author":"Amaral","year":"2007","journal-title":"Trends in Pharmacological Sciences"},{"issue":"6","key":"10.1002\/14651858.CD009841.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/humu.10041","article-title":"Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening","volume":"19","author":"Bobadilla","year":"2002","journal-title":"Human Mutation"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0108|cit108","unstructured":"Hospital for Sick Children in Toronto Cystic Fibrosis Mutation Database www.genet.sickkids.on.ca\/StatisticsPage.html"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0109|cit109","unstructured":"Deeks J Higgins J Altman D Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD009841.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0022-3476(98)70441-X","article-title":"Comparison of the clinical manifestations of cystic fibrosis in black and white patients","volume":"132","author":"Hamosh","year":"1998","journal-title":"Journal of Pediatrics"},{"issue":"7414","key":"10.1002\/14651858.CD009841.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0112|cit112","unstructured":"Higgins JPT Altman DG (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0113|cit113","unstructured":"Higgins JPT Deeks JJ Altman DG on behalf of the Cochrane Statistical Methods Group Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD009841.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ddmec.2004.08.012","article-title":"Cystic fibrosis: disease mechanisms and therapeutic targets","volume":"1","author":"McKone","year":"2004","journal-title":"Drug Discovery Today: Disease Mechanisms"},{"issue":"6","key":"10.1002\/14651858.CD009841.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"issue":"4922","key":"10.1002\/14651858.CD009841.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"issue":"5","key":"10.1002\/14651858.CD009841.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1469-1809.2003.00028.x","article-title":"The phenotypic consequences of CFTR mutations","volume":"67","author":"Rowntree","year":"2003","journal-title":"Annals of Human Genetics"},{"issue":"2","key":"10.1002\/14651858.CD009841.pub2-BIB0118|cit118","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010966","article-title":"Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis","author":"Sinha","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD009841.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/adc.76.3.278","article-title":"Delta F508 in cystic fibrosis: Willing but not able","volume":"76","author":"Southern","year":"1997","journal-title":"Archives of Disease in Childhood"},{"issue":"3","key":"10.1002\/14651858.CD009841.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000102068","article-title":"Cystic fibrosis and formes frustes of CFTR-related disease","volume":"74","author":"Southern","year":"2007","journal-title":"Respiration: International Review of Thoracic Diseases"},{"key":"10.1002\/14651858.CD009841.pub2-BIB0121|cit121","unstructured":"UK CF Trust Cystic fibrosis: our focus www.cysticfibrosis.org.uk\/media\/598466\/annual-data-report-2013-jul14.pdf"},{"issue":"44","key":"10.1002\/14651858.CD009841.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.","volume":"106","author":"Goor","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"18","key":"10.1002\/14651858.CD009841.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18180","article-title":"Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis","volume":"18","author":"Whiting","year":"2014","journal-title":"Health Technology Assessment (Winchester, England)"}],"updated-by":[{"DOI":"10.1002\/14651858.cd009841.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD009841.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:37:26Z","timestamp":1628548646000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD009841.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,3,26]]},"references-count":123,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009841.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD009841.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,26]]}}}